Morgan Stanley analyst Sean Laaman maintained a Buy rating on Centessa Pharmaceuticals today and set a price target of $27.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sean Laaman has given his Buy rating due to a combination of factors that highlight Centessa Pharmaceuticals’ promising position in the market. The company’s ORX750 drug has demonstrated superior efficacy in recent trials compared to competitors, particularly in its ability to achieve a higher Maintenance of Wakefulness Test (MWT) score in a shorter treatment duration.
The emerging data suggests that ORX750 could be considered best-in-class within the orexin-2 landscape, especially given its well-tolerated profile and significant MWT outcomes. These factors, combined with the potential for ORX750 to perform well across various patient populations, underpin Laaman’s positive outlook on Centessa’s stock.
Laaman covers the Healthcare sector, focusing on stocks such as Neurocrine, Jazz Pharmaceuticals, and Exelixis. According to TipRanks, Laaman has an average return of 8.5% and a 61.35% success rate on recommended stocks.
In another report released on November 10, LifeSci Capital also maintained a Buy rating on the stock with a $49.00 price target.